All articles
Building a Pharmacovigilance System Master File That Survives Inspection
What a PSMF has to contain, why inspectors read it as a promise to be tested, and the maintenance discipline that keeps it from becoming fiction.
Preclinical & ClinicalGLP Compliance in Preclinical Studies: Where Programmes Lose Data
Why preclinical data gets rejected, the three GLP controls that decide whether a study is reconstructable, and what happens when a pivotal study cannot be defended.
Preclinical & ClinicalIND vs. CTA: Two Filings, One Data Set
How a US IND and an EU clinical trial application differ in mechanics, what genuinely transfers between them, and the sequencing decision that saves a quarter.
Talent & StaffingBuild vs. Borrow: When an In-House QA Department Stops Making Sense
A framework for deciding which quality roles to hire and which to contract, based on continuity, peak load and how often you genuinely need deep specialism.
Talent & StaffingWhat a Qualified Person Actually Certifies, and What They Refuse To
What a Qualified Person's signature actually asserts, why it cannot be given under instruction, and what happens when a QP declines to certify.
Training & CultureWhy GxP Training Fails, and What Effectiveness Measurement Looks Like
Why completion rates measure nothing useful, what effectiveness assessment actually requires, and how to build a curriculum by role rather than by regulation.
Training & CultureTraining Records Under Inspection: The Documentation Chain
The chain an inspector follows from a named person to a dated training record, the four links that usually break, and what to do about historical gaps.
Proof & PerspectiveFrom Finding to Closure: The Anatomy of a Remediation Programme
The four phases of a remediation programme that actually closes, why most fail at the second phase, and what effectiveness evidence a regulator will accept.
Proof & PerspectiveNo One Stands Alone: How a Consultancy Model Differs From Staff Augmentation
The practical difference between hiring a contractor and engaging a consultancy, why it matters when a problem crosses disciplines, and how to tell which you are buying.
Transatlantic BridgeUS to EU: The Regulatory Roadmap for a First Transatlantic Filing
The sequence a US sponsor has to follow to file in Europe, the roles that must exist before submission, and the four gaps that most often delay a first EU filing.
Transatlantic BridgeFDA vs. EMA: Where GxP Expectations Actually Diverge
The FDA and the EMA converge on principle and diverge on execution. The three divergences that cost sponsors the most, and why a shared inspection outcome is not guaranteed.
GxP Quality SystemsHow to Build a Compliant GxP Quality Management System
The build order for a GxP quality system that scales, why writing SOPs first is the wrong start, and the point at which a system becomes too heavy to follow.
Auditing & InspectionsHow to Prepare for an EMA GMP Inspection: A 90-Day Plan
What to do in the ninety days before an EU GMP inspection, why writing new procedures late makes things worse, and how the back room decides the outcome.
Auditing & InspectionsReading an FDA Form 483: What Each Observation Is Really Telling You
How to read a Form 483 for what it actually signals: what the ordering means, why the cited regulation matters more than the wording, and what determines escalation.
PharmacovigilanceThe QPPV Role Explained: Responsibilities, Liability and Residency
What a Qualified Person for Pharmacovigilance is accountable for, why residency and authority are inspected first, and how the role fails on paper.
GxP Quality SystemsWhat Is GxP? A Plain-Language Definition for Non-Specialists
A working definition of the GxP family, who each practice binds, and why treating it as end-of-line paperwork is what fails inspections.